Categories: News

NextGen Healthcare to Host Fiscal 2022 Fourth Quarter and Year-End Results Conference Call on May 17

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ATLANTA–(BUSINESS WIRE)–NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of innovative, cloud-based healthcare technology solutions, today announced it will release its fiscal 2022 fourth quarter and full-year ended March 31, 2022 operating results on Tuesday, May 17, 2022 after market close, with a conference call to follow at 5:00 p.m. Eastern Time.

Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 866-831-8713 or 203-518-9822 for international callers and referencing participant code NXGNQ422 approximately 15 minutes prior to the call. A recording of the live webcast will be available on investor.nextgen.com after the call. It will be archived for 90 days.

About NextGen Healthcare, Inc.

NextGen Healthcare, Inc. (Nasdaq: NXGN) is a leading provider of innovative healthcare technology solutions. We are reimagining ambulatory healthcare with award-winning solutions that enable high-performing practices to create healthier communities. We partner with medical, behavioral and dental providers in their journey toward whole person health and value-based care. Our highly integrated, intelligent and interoperable solutions go beyond EHR and Practice Management to increase clinical quality and productivity, enrich the patient experience and drive superior financial performance. We are on a quest to achieve better healthcare outcomes for all. Learn more at nextgen.com, and follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Contacts

Investor Relations Contact
Matthew Scalo

(415) 370-9202

mscalo@nextgen.com

Staff

Recent Posts

GE HealthCare drives innovation in theranostics with latest technological advances

GE HealthCare is helping advance clinical and operational excellence in theranostics and molecular imaging through…

15 hours ago

Saudi Arabia Concludes Landmark BIO 2025 Debut as Kingdom Opens Doors to Global Biotech Collaboration

From genomics to regulatory innovation, the Kingdom’s presence in Boston establishes it as a major…

15 hours ago

Enzon and Viskase Enter into Merger Agreement

Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined companyCRANFORD,…

15 hours ago

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people…

15 hours ago